The phase three clinical trial reached a milestone with its first American participant receiving treatment, advancing ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U ...

Seven years after the activation of the prostate biopsy service using Fusion technology, one of the most advanced innovations ...

Can PSA derivatives reduce unnecessary prostate MRI after negative biopsy? Learn how simple markers may guide imaging ...

Prostate cancer is the second-leading cause of cancer death in American men.About 1 in 8 men will be diagnosed with prostate ...

Model was developed from the prostate cancer screening group of the PLCO and validated externally in a VA population ...

Investigators designed and externally validated a prostate cancer death prediction model for risk stratification of men at the point of PSA screening.

Cribriform-negative disease had a low metastasis rate unaffected by treatment. After radiation therapy with neoadjuvant ADT group, men with cribriform-positive disease had the same metastasis rate as ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed ...

Decision making is evidence based and must be shielded from lobbying The NHS draft recommendation against routine prostate ...